Trials / Unknown
UnknownNCT05537987
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
A Multicenter, Open-Label Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- InnoCare Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
During this study, dose escalation will be conducted in subjects with advanced solid tumors who have experienced treatment failure after clinical standard of care treatments or who currently have no effective treatment available to evaluate the safety, tolerability, and PK of ICP-723
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-723 | 3+3 dose escalation |
Timeline
- Start date
- 2021-07-30
- Primary completion
- 2023-11-01
- Completion
- 2024-07-01
- First posted
- 2022-09-13
- Last updated
- 2023-01-20
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05537987. Inclusion in this directory is not an endorsement.